Outcomes in patients with clinical Stage III NSGCT who achieve complete clinical response to chemotherapy at extraretroperitoneal disease site Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Lymph Node Excision
  • Neoplasms, Germ Cell and Embryonal
  • Testicular Neoplasms

abstract

  • A CCR at the ERP disease site is associated with a greater likelihood of relapse compared with a PCR, underscoring the limitations of radiographic imaging after chemotherapy in detecting microscopic residual disease and need for rigorous monitoring of patients observed after a CCR. Furthermore, until more accurate clinical predictors of ERP histologic features are identified, we advocate for complete surgical resection of all sites of residual disease, when feasible.

publication date

  • May 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.urology.2011.11.090

PubMed ID

  • 22446341

Additional Document Info

start page

  • 1079

end page

  • 84

volume

  • 79

number

  • 5